> ## Content Index
> Fetch the complete content index at: https://www.bullished.co/llms.txt
> Use this file to discover other available public pages before exploring further.

# State Street Holds 4.3% Of Altimmune Without Seeking To Influence Its Control
- URL: https://www.bullished.co/state-street-holds-4-3-of-altimmune-without-seeking-to-influence-its-control-334bf901/
- Published: 2026-11-10T11:47:46.000Z
- Updated: 2026-11-10T11:47:46.000Z
- Description: The September 30 position came into view Tuesday, while Altimmune plans a December FDA meeting on its alcohol-use-disorder program.
- Author: Matteo Parrino
- Tags: SEC Filings, ALT, Industry: Healthcare

State Street reported a [4.3% passive stake](https://www.sec.gov/Archives/edgar/data/0000093751/000009375126000611/xslSCHEDULE%5F13G%5FX01/primary%5Fdoc.xml?ref=bullished.co) in [Altimmune](https://www.bullished.co/tag/alt/), which develops treatments for serious liver diseases, in an SEC ownership filing Tuesday. The position dates to September 30, rather than to Monday's announcement of positive results for the company's experimental drug pemvidutide in alcohol use disorder.

## 8.4 Million Shares, Passive Ownership

State Street's reported position covered 8,356,408 common shares. It had [shared voting authority](https://www.sec.gov/Archives/edgar/data/0000093751/000009375126000611/xslSCHEDULE%5F13G%5FX01/primary%5Fdoc.xml?ref=bullished.co) over 8,164,809 shares and shared authority to dispose of 8,356,408 shares.

State Street certified that the securities were obtained and held as part of its ordinary business, without a purpose or effect of changing or influencing Altimmune's control. The 4.3% figure measures beneficial ownership of the common-stock class.

## Pemvidutide's Heavy-Drinking Results

Altimmune said Monday that its mid-stage RECLAIM study in adults with moderate-to-severe alcohol use disorder met its main goal. At 24 weeks, pemvidutide recipients recorded a [4.20-day reduction](https://www.globenewswire.com/news-release/2026/11/09/3398847/0/en/altimmune-presents-new-data-from-phase-2b-impact-trial-of-pemvidutide-in-patients-with-masld-at-aasld-the-liver-meeting-2025.html?ref=bullished.co) in heavy drinking days per week, versus a 2.75-day reduction in the placebo group.

The company also said [42.2% of participants](https://www.globenewswire.com/news-release/2026/11/09/3398847/0/en/altimmune-presents-new-data-from-phase-2b-impact-trial-of-pemvidutide-in-patients-with-masld-at-aasld-the-liver-meeting-2025.html?ref=bullished.co) given pemvidutide reached zero heavy drinking days, compared with 17.4% given placebo.

Naim Alkhouri, chief medical officer of Summit Clinical Research, said no approved therapies currently address the interconnected health consequences of alcohol use disorder and alcohol-associated liver disease.

## A Drug Developer Without Approved Products

Pemvidutide is Altimmune's lead drug candidate, a weekly peptide injection that activates glucagon and GLP-1 receptors. The company is testing it for metabolic dysfunction-associated steatohepatitis, or MASH, as well as alcohol use disorder and alcohol-associated liver disease.

Altimmune has no products approved for sale; its business depends on its candidates advancing through trials and regulatory review. As of December 31, 2025, more than 700 patients had received pemvidutide across eight completed studies and two ongoing studies.

The FDA has granted the candidate Breakthrough Therapy and Fast Track designations for MASH, and Fast Track designation for alcohol use disorder. Altimmune's market value was $412 million as of 6:44 a.m. ET Tuesday.

Altimmune is scheduled to meet with the FDA in December to discuss how to design a late-stage trial program for alcohol use disorder.

Learn

- [What a Reverse Termination Fee Means: Who Pays When a Merger Collapses →](https://www.bullished.co/learn/reverse-termination-fee-meaning/)  
A reverse termination fee is paid by the buyer to the target if a merger fails on agreed terms. See how it differs from a break-up fee, with live deal examples.
- [How To Read A Merger Proxy: A Checklist For Shareholders Facing A Vote →](https://www.bullished.co/learn/merger-proxy-statement-how-to-read/)  
Facing a merger vote? Read the proxy in this order: price and payment, vote date and threshold, board background, synergy claims, then closing conditions.

### Sources

- [SCHEDULE 13G — STATE STREET CORPORATION re: ALTIMMUNE INC (ALT)](https://www.sec.gov/Archives/edgar/data/0000093751/000009375126000611/xslSCHEDULE%5F13G%5FX01/primary%5Fdoc.xml?ref=bullished.co) — SEC EDGAR
- [Altimmune's Pemvidutide Meets Primary Endpoint in Phase 2 Alcohol Use Disorder Trial](https://finance.yahoo.com/healthcare/articles/altimmune-apos-pemvidutide-meets-primary-200030550.html?.tsrc=rss&ref=bullished.co) — Yahoo Finance
- [ATNM: Introducing ATNM-400's HER3 Target](https://finance.yahoo.com/healthcare/articles/atnm-introducing-atnm-400s-her3-170000688.html?.tsrc=rss&ref=bullished.co) — Yahoo Finance
- [Vir’s ph. 3 hepatitis delta win fuels push to eclipse Gilead](https://www.fiercebiotech.com/biotech/virs-phase-3-hepatitis-delta-win-fuels-push-eclipse-gilead?ref=bullished.co) — fiercebiotech.com
- [Altimmune Presents Positive Late-Breaking Pemvidutide Data](https://www.globenewswire.com/news-release/2026/11/09/3398847/0/en/altimmune-presents-new-data-from-phase-2b-impact-trial-of-pemvidutide-in-patients-with-masld-at-aasld-the-liver-meeting-2025.html?ref=bullished.co) — globenewswire.com

### More on Altimmune

- [Altimmune Draws $10 Million From Hercules Loan, Pushing Interest-Only Period To June 2028](https://www.bullished.co/altimmune-draws-10-million-from-hercules-loan-pushing-interest-only-period-to-june-2028-7500d49d/)
- [Altimmune Brings In Two Biotech Veterans As Three Directors Plan To Retire In 2027](https://www.bullished.co/altimmune-brings-in-two-biotech-veterans-as-three-directors-plan-to-retire-in-2027-9fc8a513/)

[All Altimmune (ALT) coverage →](https://www.bullished.co/tag/alt/)